GlobeNewswire Inc.Jun 27, 4:30 AM ET▲ Positive
Listed as a leading market player with exposure to the growing vagus nerve stimulation segment, which is projected to register the fastest growth during the forecast period.
LivaNova news
$76.99−0.28%
Close Sep 29, 2026 · split-adjustedArticles · 30 days0English, de-duplicated
Positive0
Neutral0
Negative0
About LivaNova
No recent articles focused on LivaNova.
Also mentions LIVN
Articles that tag LIVN but are mainly about other companies.
GlobeNewswire Inc.Apr 23, 1:00 PM ET▲ Positive
Listed as a key company in the growing perfusion systems market with expanding applications in cardiac surgery and organ preservation, benefiting from market growth drivers.
BenzingaMar 27, 10:15 AM ET▲ Positive
Received FDA premarket approval for aura6000 hypoglossal nerve stimulation therapy for sleep apnea with 65% responder rate; developing next-generation MRI-compatible device with rechargeable battery technology for 2027 launch.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology